Fund HoldingsAisling Capital Management LP

Total Portfolio Value
$471.62M
Total Bought
$1.88M
Total Sold
$36.12M
Net Transaction
-$34.24M
Filing Period:
Securities
SharesValue ($K)
Q1 2026
Q2 2026
Change
Q1 2026
Q2 2026
Weight (%)
Change
COMPASS PATHWAYS PLC(CMPS)1,432,3361,432,33607,92120,2684.30%+12,347
MONTE ROSA THERAPEUTICS INC(GLUE)1,555,6641,555,664025,59137,6477.98%+12,056
BICARA THERAPEUTICS INC568,919568,919011,31616,8913.58%+5,575
UROGEN PHARMA LTD(URGN)108,000108,00001,9423,9740.84%+2,033
VTV THERAPEUTICS INC(VTVT)050,000+50,00001,8830.40%+1,883
ACLARIS THERAPEUTICS INC(ACRS)434,455434,45501,6292,2980.49%+669
SCHOLAR ROCK HLDG CORP(SRRK)77,03177,03103,7874,2370.90%+450
MARKER THERAPEUTICS INC(MRKR)325,370325,37004234780.10%+55
ONKURE THERAPEUTICS INC(OKUR)88,60788,60703674040.09%+37
BIOMEA FUSION INC(BMEA)2,048,7572,048,75703,1353,0120.64%-123
EUPRAXIA PHARMACEUTICALS INC(EPRX)325,000325,00002,3532,1480.46%-205
BRIDGEBIO ONCOLOGY THERAPEUT(BBOT)1,018,0181,018,01809,1117,7571.64%-1,354
SYNDAX PHARMACEUTICALS INC(SNDX)1,316,8061,316,806030,76128,7856.10%-1,975
BRIDGEBIO PHARMA INC(BBIO)5,089,6114,589,611-500,000377,955341,83472.48%-36,120
Page 1 of 1
Aisling Capital Management LP — 13F Holdings — Q2 2026 | TickerTrail